Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
29.07. | Cognition Therapeutics, Inc.: Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease | 1 | GlobeNewswire (USA) | ||
COGNITION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
21.07. | Cognition Therapeutics reports positive results for Alzheimer's drug | 3 | Investing.com | ||
21.07. | Cognition Therapeutics: Positive Studiendaten für Alzheimer-Wirkstoff Zervimesin | 1 | Investing.com Deutsch | ||
21.07. | Cognition Therapeutics, Inc.: Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease | 1 | GlobeNewswire (USA) | ||
16.07. | Cognition Therapeutics stock soars after DLB study results | 3 | Investing.com | ||
16.07. | Cognition Therapeutics: Aktie legt nach vielversprechenden Studiendaten zu Demenzmittel zu | 18 | Investing.com Deutsch | ||
16.07. | Cognition Therapeutics, Inc.: Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC | 105 | GlobeNewswire (Europe) | - Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo... ► Artikel lesen | |
12.07. | Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress | 2 | Insider Monkey | ||
10.07. | Cognition Therapeutics stock soars after FDA meeting on Alzheimer's drug | 4 | Investing.com | ||
10.07. | Cognition Therapeutics completes FDA end-of-Phase 2 meeting for Alzheimer's drug | 1 | Investing.com | ||
10.07. | Cognition Therapeutics, Inc.: Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease | 227 | GlobeNewswire (Europe) | PURCHASE, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders... ► Artikel lesen | |
04.07. | Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data | 5 | Benzinga.com | ||
03.07. | Cognition Therapeutics stock maintains Buy rating as Phase 2 trial reaches 50% enrollment | 3 | Investing.com | ||
01.07. | Cognition Therapeutics erreicht 50% Rekrutierung in Alzheimer-Studie | 11 | Investing.com Deutsch | ||
01.07. | Cognition Therapeutics' Alzheimer's study reaches 50% enrollment | 5 | Investing.com | ||
01.07. | Cognition Therapeutics, Inc.: Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target | 1 | GlobeNewswire (USA) | ||
26.06. | H.C. Wainwright maintains buy rating on Cognition Therapeutics stock | 1 | Investing.com | ||
25.06. | Cognition Therapeutics, Inc.: Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB) | 91 | GlobeNewswire (Europe) | - End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer's Disease Scheduled - - Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies - PURCHASE, N.Y., June 25... ► Artikel lesen | |
20.06. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings | ||
09.06. | H.C. Wainwright maintains $3 target on Cognition Therapeutics stock | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 96,00 | +0,47 % | Ihre wichtigsten Termine: Tyson Foods, Biontech, Adtran, Loews, VDMA und Stabilus stehen heute im Fokus! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Luxemburg:... ► Artikel lesen | |
CUREVAC | 4,656 | -0,51 % | CureVac Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
AMGEN | 247,05 | +1,15 % | Prognose-Schock vs. Prognose-Boost - Zalando, Fresenius, Beiersdorf, Qiagen, Super Micro, AMD, Amgen | Der DAX hat sich gestern erneut gut geschlagen und an die starke Performance vom Montag angeknüpft. Es gab zwar die eine oder andere Schwächephase. Trotzdem schloss der DAX 0,37 Prozent höher bei 23.846... ► Artikel lesen | |
NOVAVAX | 6,555 | +0,72 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
BIOGEN | 110,20 | -0,72 % | Biogen-Aktie: Kurs mit wenig Bewegung (114,5994 €) | Im US-amerikanischen Wertpapierhandel ist das Wertpapier von Biogen derzeit unauffällig. Die Aktie kostete zuletzt 132,69 US-Dollar. Ein geringes Kursplus von 0,38 Prozent zeigt die Kurstafel für die... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,242 | 0,00 % | Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity | Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment
Combination of oral PL7737 and tirzepatide resulted in additive... ► Artikel lesen | |
BIOXXMED | 0,250 | 0,00 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
OCUGEN | 0,838 | +1,48 % | Ocugen Provides Business Update with Second Quarter 2025 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trialActively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial... ► Artikel lesen | |
MAINZ BIOMED | 1,480 | 0,00 % | Mainz BioMed NV: Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants | BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
VIKING THERAPEUTICS | 29,940 | +9,43 % | Is Viking Therapeutics the Next Big Biotech Bet? | ||
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 10,100 | +3,50 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
BIO-GATE | 1,020 | +7,37 % | EQS-News: Bio-Gate AG: Bio-Gate veröffentlicht endgültige Zahlen 2024 und gibt positiven Ausblick für 2025 | EQS-News: Bio-Gate AG
/ Schlagwort(e): Jahresergebnis
Bio-Gate veröffentlicht endgültige Zahlen 2024 und gibt positiven Ausblick für 2025
31.07.2025 / 21:17 CET/CEST
Für... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,366 | +0,27 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen |